Nuclear Medicine Applications for Neuroendocrine Tumors

[1]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients. , 1999, Cancer biotherapy & radiopharmaceuticals.

[2]  M Bardiès,et al.  Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  P. Smith-Jones,et al.  The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours , 1998, European Journal of Nuclear Medicine.

[4]  F. Raue,et al.  Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. , 1997, Cancer research.

[5]  K. Lamborn,et al.  Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Goldenberg,et al.  Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Heinz Höfler,et al.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut , 2004, Virchows Archiv.

[8]  E. Tartour,et al.  [Neuroendocrine tumors]. , 1992, La Revue du praticien.